Purpose-Skeletal disease causes significant morbidity in mucopolysaccharidoses (MPS), and bone remodeling processes in MPS have not been well characterized. The objective of this study was to determine if biomarkers of bone turnover are abnormal in children with specific MPS disorders (i.e. MSP-I, MPS-II, and MPS-VI) compared to healthy children.
Introduction
The mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders resulting in an accumulation of complex sugars, leading progressive multi-organ system manifestations including skeletal disease [1, 2] . The accumulation of glycosaminoglycans (GAG) in MPS disorders can lead to joint contractures, abnormal gait, atlantoaxial instability, short stature, and dysostosis multiplex [3] [4] [5] . Dysostosis multiplex in the context of MPS is hypothesized to be associated with abnormalities in bone remodeling given its progressive nature [3] . There are reports of occasional fractures and osteopenia in individuals with MPS [6] [7] [8] [9] , but their etiologies are not well elucidated and may be secondary to disuse, immobility, abnormal biomechanical forces, inflammatory effects, cell autonomous effects, or some combination of these [2, 10] .
The skeleton is affected in multiple MPS disorders (e.g. MPS I, II, III, IV, VI, VII, IX) [11] . In particular, MPS I, II, and VI have quite similar skeletal phenotypes and these 3 conditions were the focus of this study. MPS-I is an autosomal recessive disorder due to alpha-L iduronidase deficiency, and the phenotype is characterized based on severity (i.e. Hurler syndrome as the more severe form [MPS-IH], and Hurler-Scheie and Scheie syndromes as the attenutated forms [MPS-IA]). MPS-II (Hunter syndrome) is an X-linked disorder due to iduronate sulfatase deficiency. MPS-VI (Maroteaux-Lamy syndrome) is an autosomal recessive condition due to arylsulfatase B deficiency. Although therapies are available for many MPS disorders, notably enzyme replacement therapy (ERT) and hematopoietic cell transplantation (HCT) [12] [13] [14] [15] [16] [17] [18] [19] [20] , their beneficial effect on the skeleton is thought to be limited if not initiated early [21] . As new therapies become available, development of biomarkers that are associated with the skeletal manifestations in MPS disorders would be helpful for clinical trials.
The MPS animal models suggest that bone remodeling could be impaired, but the data are limited and conflicting. It has been hypothesized that GAG accumulation impairs bone cellular function, as GAG accumulation has been described in bone cells (e.g. osteoblasts, osteoclasts and chondrocytes) in some MPS animal models [22] [23] [24] [25] and in a human case report [26] . Findings from the MPS I mouse model [27] suggest that osteoclast function is impaired, and other MPS animal models show that osteoclasts don't adhere properly to bone [22] .
In more common metabolic disorders of bone such as osteoporosis, biomarkers of bone turnover can help predict long-term disease severity such as fracture risk. The hypothesis is that biomarkers of bone turnover will prove helpful in predicting disease severity and in monitoring therapies for musculoskeletal complications in MPS disorders. The objective of this study wasto determine if biomarkers of bone turnover were abnormal in children with MPS I, II and VI compared to healthy children. The secondary aim was to determine if biomarkers of bone turnover were associated with physical functioning, pain, and height.
Methods
Individuals with MPS-IH, MPS-IA, II or VI (ages 5-17.9 years of age) were recruited from treating physicians from multiple centers, the MPS Society Newsletters, website and annual family meeting, and clinicaltrials.gov. The controls were previously recruited from the local community for a separate study of bone and energy metabolism (data unpublished). Informed consent was obtained from the parents or guardians of all participants and assent was obtained from all participants whenever cognitively possible (generally age 7 years or older). The protocol was approved by the Institutional Review Boards at the University of Minnesota and the National Institute of Neurological Disorders and Stroke.
Anthropometric measurements included height measured by wall mounted stadiometer (without shoes) to the nearest 0.1 cm and weight by electronic scale to the nearest 0.1 kg. Age and sex specific standard deviation scores (SDS) were calculated for weight and height using the SAS program from the Centers for Disease Control [http://www.cdc.gov/nccdphp/ dnpao/growthcharts/resources/sas.htm, accessed Dec 2012]. Pubertal Tanner stage [28] was assessed by physical examination by a trained study physician. Three groups were identified based on Tanner Biomarkers were obtained in the morning after fasting for 8 or more hours. Urine was obtained from a single void (first or second morning void). Markers of bone formation measured were serum bone-specific alkaline phosphatase (BSAP) and osteocalcin. Markers of bone resorption were urine pyridinoline (PYD) and deoxypyridinoline (DPD). Urinary DPD was measured using the MicroVue DPD EIA kit, urinary PYD was measured using the MicroVue PYD EIA kit, creatinine was measured using the MicroVue Creatinine EIA kit, and BSAP was measured in serum using the MicroVue BSAP EIA kit all from Quidel Corporation (San Diego, CA). Osteocalcin was measured in plasma using the Human Bone Panel from Millipore Corporation (Billerica, MA). In addition, serum 25-hydroxy vitamin D (25(OH)D) concentrations were also obtained and analyzed by liquid chromatography tandem mass spectroscopy at Fairview Diagnostics Laboratory, Minneapolis, MN.
Measures of physical function and pain were obtained using the Children's Health Questionnaire -Parent form 50 (CHQ-PF50). The CHQ-PF50 is a 50-item, parentcompleted questionnaire designed to measure the physical and psychosocial well-being of children between the ages of 5 and 18. The CHQ-PF50 has established reliability and validity and has been widely used in studies of chronic illness in childhood [29] [30] [31] . Items are measured on a Likert scale, summed for each subscale and linearly transformed to a 0 to 100 scale, where higher scores reflect better functioning. In this study, CHQ data were obtained only from individuals with MPS disorders.
Descriptive statistics were tabulated separately for the healthy control and MPS groups, which included the mean and standard deviation for continuous variables and frequency for categorical variables. Additive comparisons between group means were adjusted for sex and Tanner stage groups defined above and based on linear regression and the t-distribution with corresponding model degrees of freedom for confidence intervals and p-values. Multiplicative comparisons between group mean formation/resorption ratios used a log link with a poisson working variance and robust variance estimation for confidence intervals and P-values. Each biomarker and biomarker formation/resorption ratio was evaluated separately. Similarly, the association between differences in biomarker values and outcomes was based on linear regression and the t-distribution for inference. Reported degrees of freedom and test statistics follow the APA formatting style. All analyses were conducted using R v2.15.2 [32] .
Results

Participant Demographics/Treatments
Thirty-nine individuals with MPS were included (MPS-IH=19, MPS-IA=5, MPS-II=11 and MPS-VI=4) and compared to 51 controls (Table 1 ). Controls were, on average, about 2 years older than MPS individuals. All individuals with MPS had previously undergone HCT and/or were receiving ERT. Some individuals who had HCT received ERT before HCT but did not continue after. All children with MPS-IH were treated with HCT at <3 years of age. All children with MPS-IA or MPS-II were being treated with ERT. Two participants with MPS-VI were treated with HCT at ages 1.8 and 3.9 years; the other 2 participants with MPS-VI were being treated with ERT. Twelve participants with MPS were receiving treatment with human growth hormone (hGH) (5 with growth hormone deficiency) for an average of 3.2±2.5 years (range 0.3-8.5 years) and 8 with levothyroxine for hypothyroidism (all with normal free thyroxine and thyroid stimulating hormone levels at the time of the study). Four females and one male had untreated gonadal failure. Individuals with MPS had lower mean 25(OH)D concentrations compared to controls (Table I ; t(78)=6.7, p<0.001). Four of the participants (10%) with MPS had vitamin D deficiency defined as a 25(OH)D concentration <20 ng/ml, which was a significantly higher percentage of subjects compared to controls (0%; p=0.028; Fisher's exact test). No individual with MPS or healthy control had a fracture within the year prior to enrollment.
Bone Biomarkers
Unadjusted mean values for all biomarkers of bone remodeling were higher in the individuals with MPS compared to controls (Table I) . Using linear regression to evaluate the difference in biomarkers between MPS versus controls after adjusting for covariates of sex and Tanner stage group separately for each bone biomarker, only osteocalcin remained significantly higher in MPS (t(85)=3.9, p<0.001; Table II ). There were trends for both BSAP (t(84)=1.95, p=0.054) and urinary PYD (t(81)=1.75, p=0.084). Noteworthy is that results for urinary DPD and PYD were heavily influenced by one MPS individual with extremely elevated concentrations. When this individual was excluded, differences in DPD and PYD were much more attenuated: difference from control (95% CI As noted above, the control group was older, with no individuals < 8.5 years of age. When MPS individuals <8.5 years of age (presumably pre-pubertal) were excluded from the analysis (N=10), results were similar in magnitude and strength of association (data not shown).
Multiplicative comparisons of biomarker formation/resorption ratios between MPS versus control groups showed increases for BSAP/DPD, BSAP/PYD, OCN/DPD, and OCN/PYD ratios, although only statistically significant for BSAP/PYD and OCN/PYD ratios (see Table  II ).
Due to the presence of donor, non-MPS affected osteoclasts in individuals treated with HCT, we divided the MPS group by HCT versus non-HCT for further analysis. When comparing HCT and non-HCT MPS groups to controls, osteocalcin remained significantly higher in both groups (t(84)=3.95, p<0.001and t(84)=2.43, p=0.017, respectively). BSAP was also estimated to be higher for both groups compared to controls, but still did not reach statistical significance (t(83)=1.34, p=0.184 and t(83)=1.91, p=0.060, respectively). DPD and PYD were significantly higher in the HCT group (t(80)=2.07, p=0.041and t(80)=3.55, p<0.001, respectively), and lower on average in the non-HCT group, but not statistically significant (t(80)=−1.73, p=0.087and t(80)=−0.79, p=0.434, respectively). Multiplicative comparisons of biomarker formation/resorption ratios between MPS group by HCT and non-HCT versus control groups showed increases in the BSAP/DPD, BSAP/PYD, OCN/DPD, and OCN/PYD ratios for both the MPS HCT and non-HCT groups vs. controls, but were only statistically significant for the MPS non-HCT group when compared to controls (data not shown).
Association of Biomarkers with Functional Measures
Height SDS, CHQ bodily pain and CHQ physical function scores were not significantly associated with biomarkers of bone metabolism in individuals with MPS after adjusting for Tanner stage group and sex (Table III) .
Discussion
There are significant musculoskeletal abnormalities in the MPS disorders, and in a majority, dysostosis multiplex is a cardinal feature. Biomarkers of bone remodeling have not previously been evaluated in this population. Animal models suggest that bone cellular functions are abnormal in MPS disorders [22] [23] [24] [25] [26] [27] . Our data show that a marker of bone formation is different in children with MPS compared to controls, suggesting increased osteoblast activity. The differences of bone markers in MPS compared to controls may in part be due to factors such as activity level, mobility [33] , diet, and other co-morbidities. For example, 25(OH)D concentrations were lower in the MPS group and perhaps this is a consequence of less sun exposure or dietary intake that potentially could have impacted the bone remodeling markers.
We found that the most significant difference in bone biomarker levels was for a marker of bone formation. This may be related to the greater specificity of the markers of bone formation versus the markers of bone resorption that we measured, or a greater impact of the disease process on osteoblasts (bone formation) versus osteoclasts (bone resorption). Osteocalcin is predominantly synthesized by osteoblasts, whereas PYD and DPD are found in other tissues besides bone [34, 35] . In addition, we found a trend towards higher BSAP and PYD in individuals with MPS; however, no statistically significant difference was observed. DPD, a related urinary marker of bone resorption was not significantly different.
The reason for this may be because PYD originates from both bone and articular cartilage versus DPD which is not present in cartilage [34, 35] . Cartilage abnormalities with increased cartilage break down, similar to inflammatory joint disease, have been well described in MPS animal models [36] [37] [38] [39] , thus the increased PYD may reflect increased cartilage turnover rather than increased bone resorption.
The osteoclasts of MPS individuals who underwent HCT are donor-derived and bone density changes after HCT can be observed [40, 41] . When separating MPS individuals with and without HCT, the respective cohorts became small and hence conclusions are difficult. However, results for bone formation markers were relatively unchanged for both groups compared to controls, whereas bone resorption markers (DPD and PYD) became significantly increased in the HCT group consistent with other studies of children and adults treated with HCT [42] [43] [44] .
The functional significance of our findings is not certain, as we did not see statistically significant associations between markers of bone turnover and our selected health measures (i.e. CHQ bodily pain, CHQ physical function, and height SDS). As lysosomal storage disorders are rare diseases, our cohort was small which limited our power to detect such associations. Additionally, parent report measures of children's pain and physical functioning may be too distal to be directly associated with biomarkers of bone turnover.
Another limitation is the lack of younger individuals in the control group; however, we obtained similar results when the two groups had similar age distributions by excluding individuals with MPS under age 8.5 years. Also, activity levels likely impact bone turnover and our findings of increased bone biomarkers may be secondary to reduced physical activity and decreased mobility [32] , which were not directly measured in the current study. It is also important to note that the MPS group was heterogeneous, consisting of several MPS types and the various treatments (i.e. HCT, ERT), which may have impacted our ability to see associations between bone turnover markers and specific health outcomes.
Despite the limitations, this study represents a relatively large cohort of MPS individuals. The skeletal abnormalities in the MPS disorders can be debilitating and identification of surrogate markers of skeletal disease in MPS will be beneficial in avoiding radiation and high costs of radiographic procedures in monitoring the disease and responses to therapy. It is likely that modifications of current therapies and the addition of new therapies will continue for MPS disorders, and markers of bone metabolism may ultimately be helpful in determining early efficacy and monitoring disease progression of the musculoskeletal manifestations with the various therapies. Future studies with larger cohorts of children with MPS disorders are needed to better understand the potential relationship between biomarkers of bone health and children's physical function, and should include direct measures (e.g. range of motion and six-minute walk tests) and measurements of children's physical activity in daily life (e.g. accelerometry) to better understand the functional significance of these biomarkers for children's quality of life.
Conclusion
Osteocalcin was increased in children with MPS disorders, with trends for increases in BSAP and urinary PYD. This study provides evidence that bone biomarkers can potentially be used to quantify and monitor skeletal disease in MPS disorders as additional treatments (e.g., post-HCT supplemental ERT, stop codon suppression drugs, gene therapy, antiinflammatory therapy) become available for evaluation. Table 1 Participant characteristics in children with mucopolysaccharidoses and healthy control children Table 3 Association of bone markers with differences in CHQ scores and Height SDS among MPS 
